BeyondSpring Inc. (BYSI) company profile

BeyondSpring is a clinical-stage biopharmaceutical enterprise specializing in the research and advancement of novel cancer treatments for patients confronting serious unmet therapeutic needs. Its premier candidate, Plinabulin, operates as a selective immunomodulating microtubule-binding drug engineered to stimulate immune defenses and counter acquired resistance associated with immune checkpoint inhibitors across several malignancies, notably non-small cell lung cancer. In addition, the firm pursues pre-clinical small-molecule immune therapies and holds an ownership position in SEED Therapeutics, which creates targeted protein degradation drugs in conjunction with prominent pharmaceutical collaborators.

The company maintains an international research footprint featuring corporate offices in New Jersey as well as facilities located in Beijing and Dalian, China, while its affiliate operates premises in Pennsylvania. Its clinical evaluations span numerous global testing centers across the United States, China, Australia, and several South American nations. BeyondSpring is legally organized and incorporated under the laws of the Cayman Islands.

Summary of the business section of BeyondSpring's latest annual report, written by StockData.

“The initial public offering price of our ordinary shares is $20.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of February 27, 2026, we had 44 full-time employees, including 34 employed by SEED.”